---
name: Avigen Ltd
slug: avigen
site: cro
website_domain: avigen.bio
summary: Avigen offers avidity-based profiling of live immune–target cell interactions for immunotherapy discovery and preclinical validation. Its platform supports TCR-T, CAR-T, and NK programmes across solid tumour indications. Headquartered in London, United Kingdom.
tagline: Advancing immunotherapies with avidity intelligence
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: GB
tier2_domain_verified: false
updated_at: 2026-11-02T07:03:44.486Z
services_count: 2
modalities_count: 1
indications_count: 1
locations_count: 1
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Avigen Ltd

Advancing immunotherapies with avidity intelligence

Listed on cro.directory.

## Summary

Avigen offers avidity-based profiling of live immune–target cell interactions for immunotherapy discovery and preclinical validation. Its platform supports TCR-T, CAR-T, and NK programmes across solid tumour indications. Headquartered in London, United Kingdom.

## At a glance

- HQ country: GB

## Services

- Discovery Research
- Preclinical In Vitro Studies

## Modalities

- Cell Therapy

## Indications

- Oncology

## Locations

- White City (Scale Space), London, United Kingdom

## Long description

## Overview

Avigen is a UK-based company that provides avidity intelligence for immunotherapy research. Its proprietary platform measures cellular avidity to identify the immune cells most likely to drive therapeutic success.

## Services

- **Immunotherapy discovery:** identifying target-specific leads among millions of potential candidates.
- **Immunotherapy validation:** completing the immune cell data set and ranking candidates for translation.
- **Preclinical avidity insights:** translational analysis from initial lead identification through pre-IND candidate confirmation.

## Platform

- **Physiological relevance:** captures live immune–target cell interactions that better reflect in vivo behaviour.
- **High throughput:** analyses tens of thousands of single-cell interactions per run, scaling to millions.
- **Gentle:** maintains cell viability and functionality for immediate downstream testing.
- **Fully adaptable:** compatible with a range of adherent target cells and immune cell types, including TCR-T, CAR-T, and NK cells, across solid tumour indications.

Client testimonials describe high-quality data delivered on a rapid timeline and careful optimisation of difficult assay conditions.

## Related companies

- [STEMCELL Technologies Inc.](/companies/stemcell) (Discovery Research, Preclinical In Vitro Studies) — [Compare](/compare/avigen/stemcell)
- [Cyagen Biosciences](/companies/apac-cyagen) (Discovery Research, Preclinical In Vitro Studies) — [Compare](/compare/apac-cyagen/avigen)
- [IPM Biotech](/companies/ipmbiotech) (Discovery Research, Cell Therapy) — [Compare](/compare/avigen/ipmbiotech)
- [Axxam](/companies/axxam) (Discovery Research, Preclinical In Vitro Studies) — [Compare](/compare/avigen/axxam)
- [Evotec](/companies/evotec) (Discovery Research, Preclinical In Vitro Studies) — [Compare](/compare/avigen/evotec)
- [JangoCell](/companies/jangocell) (Preclinical In Vitro Studies, Cell Therapy) — [Compare](/compare/avigen/jangocell)
- [Nexus BioQuest](/companies/nexus-bioquest) (Discovery Research, Preclinical In Vitro Studies) — [Compare](/compare/avigen/nexus-bioquest)
- [Noble Life Sciences](/companies/noblelifesci) (Discovery Research, Preclinical In Vitro Studies) — [Compare](/compare/avigen/noblelifesci)

_Profile last updated: 2026-11-02T07:03:44.486Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.